10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US biotech Neurocrine Biosciences and Canada’s Xenon Pharmaceuticals today announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. 2 December 2019
Wuxi Biologics’ vaccine arm WuXi Vaccines (WV) expects to become a giant global vaccine supplier with its $240 million investment in the vaccine facility in Ireland last week, said the WuXi Vaccines chairman Chris Chen at a press meeting held on November 29 in Shanghai. 2 December 2019
Cambridge Innovation Capital (CIC), the UK venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has provided an update on its performance for the six months ended September 30, 2019, showing it has attracted £1 billion ($1.29 billion) of investments into Cambridge companies. 2 December 2019
The Australian subsidiary of AbbVie has announced the federal government’s decision to list Skyrizi (risankizumab), a new treatment option for adults living with severe chronic plaque psoriasis, which eligible Australian patients will be able to access from December 1, 2019 on the Pharmaceutical Benefits Scheme (PBS). 2 December 2019
AstraZeneca and US partner Merck & Co on Friday announced the recommendation of Lynparza (olaparib) by UK health technology assessor the National Institute for Health and Care Excellence (NICE) for maintenance treatment of relapsed, platinum-sensitive ovarian cancer in adults with a BRCA-mutation and who have had two or more courses of platinum-based chemotherapy. 30 November 2019
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). 29 November 2019
Positive news results of the SAkuraSky Study, a global Phase III clinical study of satralizumab (development code: SA237) have published in the online version of The New England Journal of Medicine (NEJM). 29 November 2019
Vancouver, Canada-based regenerative medicine company NervGen Pharma announced the appointment of Paul Brennan as president and chief executive effective immediately. 28 November 2019
Nantes, France-based biotech OSE Immunotherapeutics has agreed a deal with immuno-oncology diagnostic firm HalioDx, to conduct a translational investigation of immune biomarkers. 28 November 2019
The US Food and Drug Administration has accepted for Priority Review the New Drug Application (NDA) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally-advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. 28 November 2019
Researchers from Queen Mary University of London and Zhengzhou University, China, have developed a personalized vaccine system that could ultimately delay the onset of pancreatic cancer, they believe. 27 November 2019
Singapore-based TauRx has announced the publication of unexpected results of its drug hydromethylthionine, or LMTM, in patients with mild-to-moderate Alzheimer's disease. 27 November 2019
US drugmaker AbbVie frequently comes under fire for the money – well in excess of $100 billion – that it has earned from its mega blockbuster arthritis drug Humira (adalimumab). 27 November 2019
The Roche majority-owned Chugai has launched the 840mg intravenous infusion of Tecentriq (atezollizumab) in Japan for the treatment of PD-L1-positive triple-negative breast cancer (TNBC). 27 November 2019
Switzerland-based companies Lonza and DiNAQOR, a global gene therapy platform firm, have announced a strategic collaboration to advance the latter’s pre-clinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure. 27 November 2019
US biotech firm Evofem Biosciences announced the resubmission of its New Drug Application to the US Food and Drug Administration for its lead candidate Amphora (L-lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy. 26 November 2019
Shares in CymaBay Therapeutics closed 76% down on Monday after the company announced it was terminating its Phase IIb study of seladelpar in non-alcoholic steatohepatitis (NASH) and its recently initiated Phase II study of seladelpar in primary sclerosing cholangitis (PSC). 26 November 2019
The US Food and Drug Administration (FDA) has granted accelerated approval to Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. 26 November 2019
Canadian immuno-oncology specialist Medicenna Therapeutics has presented positive data from its Phase IIb trial of MDNA55 in people with recurrent glioblastoma (rGBM). 26 November 2019
Privately-held Swiss drugmaker Ferring Pharmaceuticals has launched a new gene therapy company, FerGene, together with Blackstone Life Sciences. 25 November 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024